Sanofi CEO: Cap drug prices

The new Sanofi CEO has some radical idea. In his first interview since taking the helm at Sanofi-Aventis, CEO Gérard Le Fur (photo) told the Financial Times that drug makers ought to cut prices and rely on volume for profits. Skyrocketing costs for new drugs "cannot continue," he said. He himself expects to focus on emerging markets for growth--and those markets can't support the kind of prices paid in more developed nations.

The free-ranging interview also touched on possible cost-cutting at Sanofi, and on potential acquisitions, perhaps in Japan. He plans to look at biotech acquisitions and at licensing deals, too, boosting the latter to 25 to 30 percent of the company's pipeline. And he predicts that Sanofi's vaccine sales will double to 20 percent of group revenue from 10 percent today.

- read the interview from the Financial Times

Related Articles:
Sanofi underscores pipeline advances, setbacks. Report
What's Warren Buffett buying now? Report
Pfizer-Sanofi match not made in heaven? Report
Sanofi stock up on Pfizer buyout talk. Report

Read more on: Sanofi-Aventis

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.